Inamoto Yoshihiro, Suzuki Ritsuro, Kuwatsuka Yachiyo, Yasuda Takahiko, Takahashi Taro, Tsujimura Akane, Sugimoto Kyoko, Oba Taku, Terakura Seitaro, Atsuta Yoshiko, Murata Makoto, Ito Masafumi, Kodera Yoshihisa, Miyamura Koichi
Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
Biol Blood Marrow Transplant. 2008 Jan;14(1):43-9. doi: 10.1016/j.bbmt.2007.06.015. Epub 2007 Dec 3.
We retrospectively studied 49 patients in a single institute to evaluate the long-term outcome of total lymphoid irradiation (TLI) conditioning for allogeneic stem cell transplantation (allo-SCT) to treat aplastic anemia (AA). Most of the patients had received transfusions and had undergone previous treatment, with 33 receiving related transplants and 16 receiving unrelated transplants. Conditioning consisted of cyclophosphamide (Cy; 200 mg/kg) plus TLI (750 cGy) for related transplantation and Cy plus total body irradiation (TBI; 500 cGy) and TLI (500 cGy) for unrelated transplantation. Antithymocyte globulin (ATG) was added for 6 of the unrelated transplantations. Graft-versus-host-disease (GVHD) prophylaxis consisted mainly of cyclosporine (CSA) and methotrexate (MTX). Graft failure developed in 2 patients (4.1%). With a median follow-up of 7 years, overall survival (OS) was 81% and was not statistically significantly different between the patients receiving related transplants and those receiving unrelated transplants. In multivariate analyses, a history of previous treatment with ATG was the sole factor associated with a worse survival rate, and the interval from diagnosis to treatment was not prognostic. The incidence of acute (grade II to IV) GVHD (aGVHD) was 23%, and that of chronic GVHD (cGVHD) was 29%. Female-to-male transplantation was the sole factor associated with chronic GVHD. B cell lymphoproliferative disorder developed only after the ATG-containing conditioning. No other secondary malignancies developed after long-term follow-up. Our findings suggest that TLI conditioning is feasible and effective for patients with AA.
我们在一家机构对49例患者进行了回顾性研究,以评估异基因干细胞移植(allo-SCT)采用全淋巴照射(TLI)预处理治疗再生障碍性贫血(AA)的长期疗效。大多数患者接受过输血治疗且曾接受过先前的治疗,其中33例接受相关供体移植,16例接受无关供体移植。相关移植的预处理方案为环磷酰胺(Cy;200 mg/kg)加TLI(750 cGy),无关供体移植的预处理方案为Cy加全身照射(TBI;500 cGy)和TLI(500 cGy)。6例无关供体移植患者加用了抗胸腺细胞球蛋白(ATG)。移植物抗宿主病(GVHD)预防主要采用环孢素(CSA)和甲氨蝶呤(MTX)。2例患者(4.1%)发生移植失败。中位随访7年,总生存率(OS)为81%,接受相关供体移植的患者与接受无关供体移植的患者之间总生存率无统计学显著差异。多因素分析显示,既往接受ATG治疗史是与生存率较差相关的唯一因素,从诊断到治疗的时间间隔无预后价值。急性(Ⅱ至Ⅳ级)移植物抗宿主病(aGVHD)发生率为23%,慢性移植物抗宿主病(cGVHD)发生率为29%。女性对男性移植是与慢性移植物抗宿主病相关的唯一因素。B细胞淋巴增殖性疾病仅在含ATG的预处理后发生。长期随访后未发生其他继发性恶性肿瘤。我们的研究结果表明,TLI预处理对AA患者是可行且有效的。